KR101174788B1 - 안정화된 프로스타글란딘 e 화합물 국소 투여 제형 - Google Patents

안정화된 프로스타글란딘 e 화합물 국소 투여 제형 Download PDF

Info

Publication number
KR101174788B1
KR101174788B1 KR1020117008180A KR20117008180A KR101174788B1 KR 101174788 B1 KR101174788 B1 KR 101174788B1 KR 1020117008180 A KR1020117008180 A KR 1020117008180A KR 20117008180 A KR20117008180 A KR 20117008180A KR 101174788 B1 KR101174788 B1 KR 101174788B1
Authority
KR
South Korea
Prior art keywords
weight
pge
parts
prostaglandin
delete delete
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020117008180A
Other languages
English (en)
Korean (ko)
Other versions
KR20110042138A (ko
Inventor
와이 죠셉 모
다니엘 더블유 프랭크
Original Assignee
넥스메드 홀딩스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 넥스메드 홀딩스 인코포레이티드 filed Critical 넥스메드 홀딩스 인코포레이티드
Publication of KR20110042138A publication Critical patent/KR20110042138A/ko
Application granted granted Critical
Publication of KR101174788B1 publication Critical patent/KR101174788B1/ko
Assigned to 페링 인터내셔널 센터 에스 에이 reassignment 페링 인터내셔널 센터 에스 에이 권리의 전부이전등록 Assignors: 넥스메드 홀딩스 인코포레이티드
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020117008180A 2003-01-03 2003-12-31 안정화된 프로스타글란딘 e 화합물 국소 투여 제형 Expired - Fee Related KR101174788B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/336,481 2003-01-03
US10/336,481 US6841574B2 (en) 2003-01-03 2003-01-03 Topical stabilized prostaglandin E compound dosage forms
PCT/US2003/041658 WO2004062632A1 (en) 2003-01-03 2003-12-31 Topical stabilized prostaglandin e compound dosage forms

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020057012502A Division KR20050098853A (ko) 2003-01-03 2003-12-31 안정화된 프로스타글란딘 e 화합물 국소 투여 제형

Publications (2)

Publication Number Publication Date
KR20110042138A KR20110042138A (ko) 2011-04-22
KR101174788B1 true KR101174788B1 (ko) 2012-08-20

Family

ID=32681022

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020117008180A Expired - Fee Related KR101174788B1 (ko) 2003-01-03 2003-12-31 안정화된 프로스타글란딘 e 화합물 국소 투여 제형
KR1020057012502A Withdrawn KR20050098853A (ko) 2003-01-03 2003-12-31 안정화된 프로스타글란딘 e 화합물 국소 투여 제형

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020057012502A Withdrawn KR20050098853A (ko) 2003-01-03 2003-12-31 안정화된 프로스타글란딘 e 화합물 국소 투여 제형

Country Status (16)

Country Link
US (1) US6841574B2 (cg-RX-API-DMAC7.html)
EP (1) EP1585483B1 (cg-RX-API-DMAC7.html)
JP (2) JP2006514068A (cg-RX-API-DMAC7.html)
KR (2) KR101174788B1 (cg-RX-API-DMAC7.html)
CN (1) CN100574763C (cg-RX-API-DMAC7.html)
AT (1) ATE468098T1 (cg-RX-API-DMAC7.html)
AU (1) AU2003300113B2 (cg-RX-API-DMAC7.html)
BR (1) BR0317924A (cg-RX-API-DMAC7.html)
CA (1) CA2512015C (cg-RX-API-DMAC7.html)
DE (1) DE60332656D1 (cg-RX-API-DMAC7.html)
DK (1) DK1585483T3 (cg-RX-API-DMAC7.html)
ES (1) ES2343246T3 (cg-RX-API-DMAC7.html)
IL (1) IL169425A (cg-RX-API-DMAC7.html)
PT (1) PT1585483E (cg-RX-API-DMAC7.html)
WO (1) WO2004062632A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200505321B (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050004226A1 (en) * 1998-12-10 2005-01-06 Nexmed (Holdings), Inc. Compositions and methods for amelioration of human female sexual dysfunction
GB0222522D0 (en) 2002-09-27 2002-11-06 Controlled Therapeutics Sct Water-swellable polymers
US20050181030A1 (en) * 2003-01-03 2005-08-18 Mo Y. J. Topical stabilized prostaglandin E compound dosage forms
KR101086147B1 (ko) 2003-03-21 2011-11-25 넥스메드 홀딩스 인코포레이티드 조루증 치료용 조성물 및 치료 방법
US20050113274A1 (en) * 2003-11-22 2005-05-26 Nadir Buyuktimkin Hydrocarbyl aminohydrocarbonoates and aminohydrocarbonol hydrocarbonoates as antimicrobial and antiviral agents
GB0417401D0 (en) * 2004-08-05 2004-09-08 Controlled Therapeutics Sct Stabilised prostaglandin composition
WO2006133048A2 (en) * 2005-06-03 2006-12-14 Duramed Pharmaceuticals, Inc. Pharmaceutical compositions comprising prostanoid-receptor agonists and methods of making and using the same
ITMI20051417A1 (it) * 2005-07-22 2007-01-23 Mipharm S P A Formulazione topica in forma di gel contenente come ingredienti attivi ciclovit e lidocaina
AU2006322050A1 (en) * 2005-12-06 2007-06-14 Monosol Rx, Llc Topical film compositions for delivery of actives
GB0613333D0 (en) 2006-07-05 2006-08-16 Controlled Therapeutics Sct Hydrophilic polyurethane compositions
GB0613638D0 (en) 2006-07-08 2006-08-16 Controlled Therapeutics Sct Polyurethane elastomers
US7560489B2 (en) * 2006-10-11 2009-07-14 Nexmed Holdings, Inc. Stabilized prostaglandin E composition
GB0620685D0 (en) * 2006-10-18 2006-11-29 Controlled Therapeutics Sct Bioresorbable polymers
EP2437684B1 (en) 2009-06-03 2022-06-15 ForSight Vision5, Inc. Anterior segment drug delivery
WO2012139033A1 (en) 2011-04-07 2012-10-11 Nexmed Holdings, Inc. Methods and compositions for treating raynaud's disease
CA2848397C (en) 2011-09-14 2022-04-26 Forsight Vision5, Inc. Ocular insert apparatus and methods
WO2014066775A1 (en) 2012-10-26 2014-05-01 Forsight Vision5, Inc. Ophthalmic system for sustained release of drug to eye
US8900625B2 (en) * 2012-12-15 2014-12-02 Nexmed Holdings, Inc. Antimicrobial compounds and methods of use
EP3283004A4 (en) 2015-04-13 2018-12-05 Forsight Vision5, Inc. Ocular insert composition of semi-crystalline or crystalline pharmaceutically active agent
WO2019142015A1 (es) * 2018-01-18 2019-07-25 Caicedo Pinto, David Felipe Composicion farmaceutica para la disfuncion erectil de administracion transdermica via uretral en gotas

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001051053A1 (en) * 2000-01-10 2001-07-19 Nexmed Holdings, Inc. Prostaglandin compositions and methods of treatment for male erectile dysfunction

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3883576A (en) * 1971-02-02 1975-05-13 Upjohn Co Prostaglandin E{HD 3 {B analogs
US3826823A (en) * 1972-09-25 1974-07-30 Syntex Inc Stabilized prostaglandin preparations
US3875300A (en) * 1972-12-18 1975-04-01 Ortho Pharma Corp Composition for sustained release of a medicament and method of using same
US4136162A (en) * 1974-07-05 1979-01-23 Schering Aktiengesellschaft Medicament carriers in the form of film having active substance incorporated therein
US5017382A (en) * 1979-03-21 1991-05-21 National Research Development Corporation Controlled release compositions (II)
JPS5770816A (en) * 1980-10-17 1982-05-01 Ono Pharmaceut Co Ltd Multilayered film preparation of prostagladin of prolonged action
JPS58134019A (ja) * 1982-02-05 1983-08-10 Ono Pharmaceut Co Ltd プロスタグランジン含有持続放出型三層状フイルム製剤及びその製造方法
JPS5948409A (ja) * 1982-09-10 1984-03-19 Teikoku Seiyaku Kk 矯正的歯牙移動促進剤
JPS6185315A (ja) * 1984-10-04 1986-04-30 Teikoku Seiyaku Kk シ−ト状製剤
IE59361B1 (en) * 1986-01-24 1994-02-09 Akzo Nv Pharmaceutical preparation for obtaining a highly viscous hydrogel or suspension
US5219885A (en) * 1987-02-16 1993-06-15 Froelich Juergen Prostaglandin E1 derivatives as pharmaceutically active agents, and pharmaceutical compositions containing these compounds, especially for transcutaneous administration
BR9203277A (pt) * 1992-08-21 1994-03-01 Cesar Roberto Dias Nahoum Utilizaccao de drogas eretogenicas e respectivas metodologias de aplicacao
US5380760A (en) * 1993-11-19 1995-01-10 Minnesota Mining And Manufacturing Company Transdermal prostaglandin composition
SE9501670L (sv) * 1995-05-05 1996-06-10 Perstorp Ab Omläggningsset
US20020004529A1 (en) * 1997-10-20 2002-01-10 Gary W. Neal Methods, compositions, and kits for enhancing female sexual desire and responsiveness
US6593369B2 (en) * 1997-10-20 2003-07-15 Vivus, Inc. Methods, compositions, and kits for enhancing female sexual desire and responsiveness
US6046244A (en) * 1997-11-05 2000-04-04 Nexmed Holdings, Inc. Topical compositions for prostaglandin E1 delivery
US6414028B1 (en) * 1997-11-05 2002-07-02 Nexmed Holdings, Inc. Topical compositions containing prostaglandin E1
US5942545A (en) * 1998-06-15 1999-08-24 Macrochem Corporation Composition and method for treating penile erectile dysfunction
IL140475A0 (en) * 1998-06-25 2002-02-10 Lavipharm Lab Inc A device and method for the treatment of erectile dysfunction
KR100402334B1 (ko) * 2000-06-23 2003-10-22 환인제약 주식회사 알프로스타딜 외용제

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001051053A1 (en) * 2000-01-10 2001-07-19 Nexmed Holdings, Inc. Prostaglandin compositions and methods of treatment for male erectile dysfunction

Also Published As

Publication number Publication date
CN100574763C (zh) 2009-12-30
CN1756532A (zh) 2006-04-05
PT1585483E (pt) 2010-06-17
US20040131664A1 (en) 2004-07-08
ATE468098T1 (de) 2010-06-15
JP2006514068A (ja) 2006-04-27
EP1585483A4 (en) 2006-04-19
US6841574B2 (en) 2005-01-11
CA2512015A1 (en) 2004-07-29
WO2004062632A1 (en) 2004-07-29
JP5395138B2 (ja) 2014-01-22
JP2012036196A (ja) 2012-02-23
AU2003300113A1 (en) 2004-08-10
KR20050098853A (ko) 2005-10-12
AU2003300113B2 (en) 2010-03-11
EP1585483B1 (en) 2010-05-19
BR0317924A (pt) 2005-11-29
HK1090293A1 (zh) 2006-12-22
EP1585483A1 (en) 2005-10-19
CA2512015C (en) 2011-11-08
DE60332656D1 (de) 2010-07-01
ES2343246T3 (es) 2010-07-27
IL169425A (en) 2010-11-30
ZA200505321B (en) 2006-04-26
DK1585483T3 (da) 2010-07-19
KR20110042138A (ko) 2011-04-22

Similar Documents

Publication Publication Date Title
JP5395138B2 (ja) 局所安定化プロスタグランジンe化合物剤形
JP2014055144A (ja) 局所安定化プロスタグランジンe化合物剤形
KR100462442B1 (ko) 국소용 프로스타글란딘 조성물을 제조하는 방법
KR101400359B1 (ko) 안정화된 프로스타글란딘 e 조성물
US6500440B1 (en) Topical preparation of alprostadil for the treatment of erectile dysfunction
HK1090293B (en) Topical stabilized prostaglandin e compound dosage forms
AU2014201174B2 (en) Stabilized prostaglandin e composition

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A18-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

Fee payment year number: 1

St.27 status event code: A-2-2-U10-U12-oth-PR1002

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

FPAY Annual fee payment

Payment date: 20150724

Year of fee payment: 4

PR1001 Payment of annual fee

Fee payment year number: 4

St.27 status event code: A-4-4-U10-U11-oth-PR1001

FPAY Annual fee payment

Payment date: 20160726

Year of fee payment: 5

PR1001 Payment of annual fee

Fee payment year number: 5

St.27 status event code: A-4-4-U10-U11-oth-PR1001

FPAY Annual fee payment

Payment date: 20170719

Year of fee payment: 6

PR1001 Payment of annual fee

Fee payment year number: 6

St.27 status event code: A-4-4-U10-U11-oth-PR1001

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

Not in force date: 20180811

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

St.27 status event code: A-4-4-U10-U13-oth-PC1903

PC1903 Unpaid annual fee

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20180811

St.27 status event code: N-4-6-H10-H13-oth-PC1903